ReviewOncoTargets and therapy2016
Prognostic role of microRNA-150 in various carcinomas: a meta-analysis.
Review in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Utility of miR‑133a‑3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta‑analysis and bioinformatics.Molecular medicine reports · 2018Pooled it
- Downregulation of miR-145 alleviates ox-LDL-induced inflammation by targeting QKI in macrophages.American journal of translational research · 2022Article
- Article
- Article
- Diagnostic and Prognostic Significance of MiR-150 in Colorectal Cancer: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2020Review
- DNA Methylation Influences miRNA Expression in Gonadotroph Pituitary Tumors.Life (Basel, Switzerland) · 2020Article
- miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma.Oncology letters · 2020Article
- Reduced atherosclerosis lesion size, inflammatory response in miR-150 knockout mice via macrophage effects.Journal of lipid research · 2018Article
- MicroRNA-150 targets ELK1 and modulates the apoptosis induced by ox-LDL in endothelial cells.Molecular and cellular biochemistry · 2017Article
- Letter to the editor regarding "Prognostic role of microRNA-150 in various carcinomas: a meta-analysis".OncoTargets and therapy · 2017Article
- Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMicroRNA-150 (miR-150) was revealed to be an attractive prognostic biomarker in recent studies. However, the prognostic significance of miR-150 expression in cancer remains inconclusive. The aim of this study was to summarize the global predicting role of miR-150 in survival in patients with various carcinomas.
methodsEligible studies were identified through multiple search strategies. Data were extracted from the studies by investigating the relationship between miR-150 expression and survival in patients with cancer. A meta-analysis of the hazard ratio (HR) was then performed to evaluate the prognostic role of miR-150 in different tumors. Pooled HRs of miR-150 for overall survival and progression-free survival were calculated to measure the effect of miR-150 expression on prognosis.
resultsThis meta-analysis included nine published studies concerning various carcinomas. Our results indicate that an elevated miR-150 expression is associated with an enhanced overall survival in the digestive tract cancer subgroup (HR =0.57, 95% confidence interval [CI]: 0.37-0.90) and a poor progression-free survival in various cancers (HR =3.08, 95% CI: 2.00-4.75).
conclusionmiR-150 may have the potential to become a new useful prognostic factor to monitor cancer prognosis and progression. However, given the current insufficient relevant data, further clinical studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.